Argos Therapeutics (ARGSQ) Stock Price, News & Analysis

Company Overview

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.02 to $0.25
• Volume: N/A
• Average Volume: 13,394 shs
• Market Capitalization: $571,698.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARGSQ Stock Analysis - Frequently Asked Questions

How have ARGSQ shares performed this year?

Argos Therapeutics' stock was trading at $0.0540 at the beginning of the year. Since then, ARGSQ shares have increased by 0.0% and is now trading at $0.0540.
View the best growth stocks for 2025 here.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analysts' expectations of $0.10 million.

When did Argos Therapeutics' stock split?

Shares of Argos Therapeutics reverse split on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/09/2017
• Today: 5/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ARGSQ
• CIK: 1105533
• Web: www.argostherapeutics.com
• Phone: 919-287-6300
• Fax: N/A
• Employees: 122
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.90 million
• Price / Sales: 0.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.63) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 10,587,000
• Free Float: N/A
• Market Cap: $571,698.00
• Optionable: Not Optionable
• Beta: 2.47